Oral APX3330 Receives FDA Nod for Phase 3 Endpoint in Diabet

Ocuphire's end-of-phase 2 meeting with the FDA supports APX3330's phase 3 advancement, with 3-step worsening in binocular DRSS score as the primary endpoint.

Related Keywords

United States , America , American , Arshad Khanani , David Brown , George Magrath , Drug Administration , Ocuphire Pharma Inc , American Academy Of Ophthalmology , Sierra Eye Associates , Special Protocol Assessment , Retina Consultants , Annual American Academy ,